

H Arzu YaÅar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2655510/publications.pdf>

Version: 2024-02-01

12
papers

64
citations

1684188

5
h-index

1588992

8
g-index

12
all docs

12
docs citations

12
times ranked

70
citing authors

#	ARTICLE	IF	CITATIONS
1	Central nervous system involvement in patients with acute myeloid leukemia. Turkish Journal of Medical Sciences, 2021, 51, 2351-2356.	0.9	2
2	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2020, 26, 267-272.	0.9	8
3	Kaposi sarcoma associated with rituximab-based cytotoxic therapy. Journal of Oncology Pharmacy Practice, 2020, 26, 220-223.	0.9	5
4	The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. Journal of Oncology Pharmacy Practice, 2020, 26, 1110-1116.	0.9	19
5	Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos) Tj ETQq1 1 0.784314 rgBT /Overl European Journal of Cancer Care, 2020, 29, e13296.	1.5	3
6	Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature. Journal of Oncology Pharmacy Practice, 2020, 26, 1762-1764.	0.9	7
7	A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 972-981.	0.9	5
8	Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice, 2020, 26, 1583-1589.	0.9	6
9	Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?. Journal of Oncology Pharmacy Practice, 2019, 25, 2062-2063.	0.9	0
10	Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2019, 25, 1658-1664.	0.9	7
11	Targeted Agents and Resistance Mechanism in Renal Cell Cancer. Åæronkoloji BÅ¼lteni, 2019, 18, 73-79.	0.1	1
12	Clinicopathological associations of acquired erythroblastopenia. International Journal of Clinical and Experimental Medicine, 2015, 8, 22515-9.	1.3	1